I re- read the paper . There is no mention of IA or reason for halt/hold. Maybe they provided you with a limited edition of paper to read or you were hallucinating while reading it .
And since everyone like ChatGPT , here is what it said about discussing IA even after trial
Pharmaceutical companies may report interim analysis results of a trial under certain conditions. These conditions include:
1. **Regulatory Requirements**: Some regulatory agencies may require the reporting of interim results, especially if they impact patient safety or the continuation of the trial.
2. **Clinical Trial Agreements**: Agreements with clinical trial sites or sponsors might stipulate the reporting of interim results.
3. **Public Interest**: If the interim results are significant and could impact public health, companies might choose to report them.
4. **Stock Market Regulations**: Publicly traded companies may need to disclose material information that could affect their stock price.
5. **Scientific and Ethical Considerations**: Researchers may publish interim results in scientific journals or conferences, particularly if the data could contribute to the scientific community.
Interim results are often carefully managed to ensure that the trial's integrity is maintained, and they are typically subject to strict confidentiality protocols.
News 
Market Data 
Discover 
